Boardroom Alpha
Boardroom Alpha
AMN · Current Report (Form 8-K) · Filed May 4, 2026

Amn Healthcare Services Inc — Current Report (Form 8-K)

Form
8-K
Filed
May 4, 2026
Period
May 1, 2026
Ticker
AMN
Accession
0001104659-26-054478
Boardroom Alpha · Filing insights

Shareholders approved Amendment No. 1 to the AMN Healthcare 2025 Equity Plan at the 2026 Annual Meeting.

About Amn Healthcare Services Inc
Market cap
$1.2B
1Y TSR
+26.6%
3Y TSR
−36.4%
Board grade
C-
Sector
Healthcare
CEO
Caroline Grace
Last annual meeting: May 1, 2026 · View full Amn Healthcare Services Inc profile →

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): May 1, 2026

 

AMN HEALTHCARE SERVICES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 001-16753 06-1500476
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)

 

2999 Olympus Boulevard, Suite 500
Dallas, Texas 75019

(Address of principal executive offices) (Zip Code)  

 

(866) 871-8519

(Registrant’s Telephone Number, Including Area Code)  

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange
on which registered
Common Stock, par value $0.01 per share   AMN   NYSE

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

The Board of Directors of AMN Healthcare Services, Inc. (the “Company”) previously approved, subject to shareholder approval, Amendment No. 1 to the AMN Healthcare 2025 Equity Plan (the “Amendment”). The Company’s shareholders approved the Amendment at the Annual Meeting of Shareholders of the Company held on May 1, 2026 (the “Annual Meeting”). A description of the material terms of the Amendment is included in the Company’s Definitive Proxy Statement on Schedule 14A for the Annual Meeting, filed with the Securities and Exchange Commission on March 18, 2026 (the “Proxy Statement”).

 

The description of the Amendment is qualified in its entirety by reference to the full text of the Amendment, which is filed as Exhibit 10.1 hereto, and incorporated herein by reference.

 

Item 5.07.Submission of Matters to a Vote of Security Holders.

 

At the Annual Meeting held on May 1, 2026, the Company’s shareholders voted on five proposals as set forth below, each of which is described in greater detail in the Proxy Statement. The number of votes cast for and against, and the number of abstentions and broker non-votes, with respect to each matter voted upon are set forth below.

 

1.The individuals listed below were elected at the Annual Meeting by the vote set forth in the table immediately below to serve as directors of the Company until the next annual meeting of shareholders or until their respective successors have been duly elected and qualified:

 

  Directors     For       Against       Abstain     Broker Non-Votes
  Jorge A. Caballero     29,074,412       751,635       13,369     4,410,527
  Mark G. Foletta     28,893,557       931,182       14,677     4,410,527
  Teri G. Fontenot     29,044,752       751,910       42,754     4,410,527
  Cary S. Grace     29,368,298       429,669       41,449     4,410,527
  James H. Hinton     29,157,914       667,924       13,578     4,410,527
  Celia P. Huber     29,135,486       691,598       12,332     4,410,527
  Daphne E. Jones     29,059,550       766,463       13,403     4,410,527
  Eric P. Palmer     29,442,400       383,258       13,758     4,410,527
  Sylvia D. Trent-Adams     27,703,487       2,121,512       14,417     4,410,527

 

2.The approval, on an advisory basis, of the compensation paid to the Company’s named executive officers, as described in the Proxy Statement. This proposal was approved as set forth immediately below:

 

  For       Against       Abstain     Broker Non-Votes
  22,728,186       7,071,111       40,119     4,410,527

 

3.The ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. This proposal was approved as set forth immediately below:

 

  For       Against       Abstain     Broker Non-Votes
  33,170,877       1,064,827       14,239    

 

4.The approval of Amendment No. 1 to the AMN Healthcare 2025 Equity Plan. This proposal was approved as set forth immediately below:

 

  For       Against       Abstain     Broker Non-Votes
  28,909,689       895,750       33,977     4,410,527

 

5.The shareholder proposal entitled “Independent Board Chairman.” This proposal was not approved as set forth immediately below:

 

  For       Against       Abstain     Broker Non-Votes
  7,495,013       22,327,804       16,599     4,410,527

 

 

 

Item 9.01.Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
10.1   Amendment No. 1 to the AMN Healthcare 2025 Equity Plan.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AMN Healthcare Services, Inc.
     
Date: May 4, 2026 By: /s/ Cary Grace
  Name: Cary Grace
  Title: Chief Executive Officer

 

 

 

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Amn Healthcare Services Inc (AMN)

Reference

Frequently asked questions

When did Amn Healthcare Services Inc file this 8-K?
Amn Healthcare Services Inc (AMN) filed this Current Report (Form 8-K) with the SEC on May 4, 2026. The accession number assigned by EDGAR is 0001104659-26-054478.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Shareholders approved Amendment No. 1 to the AMN Healthcare 2025 Equity Plan at the 2026 Annual Meeting. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Amn Healthcare Services Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Amn Healthcare Services Inc has filed under CIK 1142750, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer